Cancer News and Research

Latest Cancer News and Research

Biological-based therapies are alternative medicines for women recovering from breast cancer

Biological-based therapies such as diet supplements and vitamins are the most popular complementary and alternative medicines for women recovering from breast cancer, according to a Michigan State University researcher working to create a support intervention for women in treatment for the disease.

12 Feb 2010

British rhubarb could be a potential source of anti-cancer agent

Eating rhubarb baked in a crumble is not only tasty it may also be the best way to take advantage of its health benefits, and could lead to the development of new cancer treatments.

From Sheffield Hallam University 11 Feb 2010

Emory-UGA IPIRC to host symposium on H1N1 virus

The Emory - University of Georgia Influenza Pathogenesis and Immunology Research Center will host a symposium April 18 - 20 at the Emory Conference Center featuring an international roster of speakers.

11 Feb 2010

Decline in breast cancer rates linked to race, ethnicity and economic background

Breast cancer rates are declining, but some groups have seen a more significant decline than others, with race, ethnicity and economic background playing a part.

11 Feb 2010

Mayo Clinic provides treatment options for aging skin

Age or liver spots -- These flat, brown areas, also called solar lentigos, typically occur on the hands, back and face. Using a topical retinoid -- often in conjunction with bleaching cream and a mild topical steroid -- may gradually fade an age spot.

11 Feb 2010

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

11 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. (“NeedleTech”) subsequent to its acquisition by Theragenics on July 28, 2008.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

hESC and iPSC: Long-term stem cell evaluation and comparison study

For the first time, scientists have performed a detailed long-term evaluation and comparison of two different types of pluripotent stem cells: human embryonic stem cells (hESC) and induced pluripotency stem cells (iPSC). Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells which makes them less controversial.

11 Feb 2010

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

Cancer Research UK scientists have identified the frequency of new genetic 'hotspots' which could help doctors to tailor therapies to as many as 3,000 additional bowel cancer patients each year, according to research published in the British Journal of Cancer today.

11 Feb 2010

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

4SC AG a drug discovery and development company focused on autoimmune and cancer indications, today announced the first treatment in a Phase I study evaluating 4SC-205, an oral Eg5 kinesin spindle protein inhibitor, in patients with solid tumours or malignant lymphomas.

11 Feb 2010

New campaign launched to bring attention to national asbestos problem

"Ban Asbestos Now," a campaign to build awareness of the continued use of asbestos in the United States, today launched the Ban Asbestos Now Video Search, asking students across the United States to use their creativity to draw national attention to the toxic, and often deadly, substance considered "the largest manmade public health crisis in history" according to the Asbestos Disease Awareness Organization (ADAO).

11 Feb 2010

VCU professor warns consumers to be wary of unregulated electronic cigarettes

Electronic cigarettes should be evaluated, regulated, labeled and packaged in a manner consistent with cartridge content and product effect - even if that effect is a total failure to deliver nicotine as demonstrated in a study supported by the National Cancer Institute and led by a Virginia Commonwealth University researcher.

11 Feb 2010

Oncogene has similar biochemical functions in ancestral metazoan and in humans

To find the causes for cancer, biochemists and developmental biologists at the University of Innsbruck, Austria, retraced the function of an important human cancer gene 600 million years back in time. For the first time, they have identified the oncogene myc in a fresh water polyp and they have shown that this oncogene has similar biochemical functions in ancestral metazoan and in humans.

11 Feb 2010

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) is commemorating "a decade of standing for hope" by holding a string of high profile lemonade stands, the first taking place at the Pro Bowl and Super Bowl. 2010 marks 10 years since cancer patient Alexandra "Alex" Scott (1996-2004) held her first front yard lemonade stand to find a cure for childhood cancer.

11 Feb 2010

Online fundraising now possible with new iphone application

The newest fundraising tool for participants in the 2010 Hill Country Ride for AIDS comes by way of the mobile device. The Central Texas nonprofit today launched its new iPhone® application, further equipping event participants with the technology solutions they need to reach more donors and be more successful in their peer-to-peer fundraising efforts.

11 Feb 2010

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes.

11 Feb 2010

Cancer News and Research

Latest Cancer News and Research

Biological-based therapies are alternative medicines for women recovering from breast cancer

British rhubarb could be a potential source of anti-cancer agent

Emory-UGA IPIRC to host symposium on H1N1 virus

Decline in breast cancer rates linked to race, ethnicity and economic background

Mayo Clinic provides treatment options for aging skin

3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Theragenics announces record $18.7M consolidated revenue for fourth-quarter 2009

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

hESC and iPSC: Long-term stem cell evaluation and comparison study

New genetic 'hotspots' may help doctors devise therapies for bowel cancer patients

4SC AG announces the first treatment in Phase I clinical study of 4SC-205

New campaign launched to bring attention to national asbestos problem

VCU professor warns consumers to be wary of unregulated electronic cigarettes

Oncogene has similar biochemical functions in ancestral metazoan and in humans

ALSF commemorates "a decade of standing for hope" by holding high profile lemonade stands

Online fundraising now possible with new iphone application

Research study on epigenetic phenotypes published online in the Journal of Clinical Oncology

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in